Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ASCO 2018 Chicago’

ASCO18 Reader Q&A

It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some shorter snippets as everyone will be enjoying the break outside, weather permitting!

In our latest Preview series, we address some pertinent questions that have come in from BSB readers on several topics in between AACR and ASCO, including tumour mutation burden (TMB), the PACIFIC trial, monalizumab, renal cell carcinoma (RCC) and castrate resistant prostate cancer (CRPC).

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ASCO18 Preview on Biomarkers of Response

Chicago Loop Train

In this latest ASCO 2018 Preview, we take a look at tissue and blood based biomarkers to see what we can learn and whether they look useful or not for predicting which patients should receive a therapy or not.

There’s quite a lot we can learn from the latest data from the initial abstracts ahead of the meeting in order to be better prepared about what to expect in Chicago.

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ASCO18 Preview 4 What’s Hot in Urothelial Carcinoma

Downtown Chicago

In our latest ASCO 2018 Preview series we take a look at some of the key highlights from urothelial and bladder cancers and look at how new developments in this space are progressing.

Historically in oncology, we see initial trials begin in advanced stage disease especially in the refractory metastatic setting and move up into earlier lines of therapy later as safety and efficacy become more established.

This situation has been very much the case in urothelial carcinomas, including bladder, penile, renal pelvis, ureter and transitional cell cancers. With the approval of pembrolizumab and atezolizumab in the relapsed setting following cisplatin therapy, much of the focus has now turned to earlier stage disease.

In our latest Preview, we explore some of the key combinations and look at whether or not they are more promising in terms of outcomes than the monotherapy readouts we have seen to date.  There’s a lot to cover and digest…

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ASCO18 Preview 3 – Take a Walk on Life

Well, the ASCO abstract drop has certainly brought with it some good, bad, and even confusing data to explore this year, perhaps not helped by some of the weird assumptions and misconceptions being bandied around.

In our latest preview, we take another dozen or so key topics and explore what we know and don’t know in the context of the broader landscape. We also address some of the inaccuracies out there for the unwary.

There’s a lot to learn here and the devil, as always, is in the details.

“There’s just a song in all the trouble and the strife
You do the walk, yeah, you do the walk of life
You do the walk of life.”

So grab a cup of coffee and take a walk through the minefield of initial data with us… after all, not all of it is in dire straits 😉

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ASCO18 Preview 2 – a dozen key Posters to watch out for

Following yesterday’s review of a dozen key oral abstract sessions to watch out for at ASCO18 next month including lung cancer and others, we now take a look at the other side of the coin with a dozen key poster abstracts to explore.

  • Which topics jump out this year?
  • What new targets and molecules are the emergent gems to think about?
  • What can we learn from translational and early combination clinical data?

Take a walk with us on our journey to Chicago ahead of the data drop at 5pm…

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ASCO18 Preview 1 – Magnificence or Atrocious?

The Bean, Chicago

Whenever the Bean photo pops up then you know it marks the start of the annual meeting of the American Society of Clinical Oncology (ASCO).

Ahead of this year’s abstract data palooza, I thought it would be a nice idea to highlight some of the key sessions of interest and important abstracts within.

There are quite a few new molecules to watch out for in early drug development, plus some important phase 3 trial readouts to consider, especially on the combination front.

It will be hard act to beat or even follow the phase 3 lung cancer clinical trials plenary at AACR18 last month, but here goes…

We have selected 11 key areas that may be useful to watch out for as a starting point ahead of the abstract data dump expected tomorrow at 5pm.

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

A different take on targeting cancer

While many observers attentions have recently been focused on immuno-oncology of late, particularly with respect to checkpoint blockade and CAR T cell therapies, these are not the only class of drugs that are being investigated in the clinic.

Field of dreams or crowded marketplace?

We saw a lot of early preclinical data and especially got to see quite a few new targets at AACR, while next month ASCO offers a new opportunity to see inital phase 1 data presented in several developmental therapeutic sessions and in the poster halls.

There is no doubt that the oncology R&D niche is becoming increasingly competitive and crowded, which means that companies need to think carefully about how they can clearly differentiate themselves and position their platform much more assertively than before.

For small biotechs, this also means going beyond offering great preclinical packages to demonstrating proof of concept in the clinic, hence phase 1/2 trials are receiving a lot more attention these days, as potential collaborators and acquirers flock to the poster halls.

Today we have a CEO from one of these emerging biotech companies in the BSB hotseat with a candid discussion about their approach, why they are different, and importantly, where they are heading…

To learn more and get a heads up on our latest thought leader interviews and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Stacking up evidence from IO clinical trials

What we wanted to accomplish in our latest thought leader interview was to peek under the hood with someone active in this field who is an experienced participant in phase 2 and 3 trials, as well as being a solid translational researcher capable of thinking outside the box critically.

Stacking up the evidence from IO trials

Today we cover a global KOL’s perspectives on cancers of the lung, renal, bladder, and even melanoma, in a wide ranging discussion about immunotherapy trials and some of the pitfalls and opportunities to watch out for.

It makes for an intriguing read as there are likely a few issues that many have not thought about in great depth.

This is an important discussion in the context of not just data that was recently presented at several conferences including AACR, but also with the upcoming monotherapy and chemo combination trials (including squamous and non-squamous lung cancer) expected at ASCO in a few weeks time.

We discuss quite a few of the key challenges and opportunities relating to the broader picture and highlight some of the important issues to watch out for…

To learn more from our latest thought leader interview and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!